中国血液净化

中国血液净化 ›› 2022, Vol. 21 ›› Issue (12): 898-902.doi: 10.3969/j.issn.1671-4091.2022.12.008

• 综述 • 上一篇    下一篇

新型钾结合剂在慢性肾脏病患者中的研究进展

潘金茹   阿比囡扎   董捷
  

  1. 100034 北京，1北京大学第一医院肾脏内科，北京大学肾脏疾病研究所，卫生部肾脏疾病重点实验室，教育部慢性肾脏疾病预防与治疗重点实验室，中国医学科学院免疫介导肾病诊治创新单元
  • 收稿日期:2022-05-13 修回日期:2022-08-08 出版日期:2022-12-12 发布日期:2022-12-12
  • 通讯作者: 董捷 E-mail:jie.dong@bjmu.edu.cn

Advanced progress of new potassium-binding agents for patients with chronic kidney disease

PAN Jin-ru, ABI Nan-zha, DONG Jie   

  1. Renal Division, Peking University First Hospital; Institute of Nephrology, Peking University; Key Laboratory of Renal Disease, Ministry of Health of China; Key Laboratory of Chronic Kidney Disease Prevention and Treatment (Peking University), Ministry of Education; Research Units of Diagnosis and Treatment of Immune-mediated Kidney Diseases, Chinese Academy of Medical Sciences; Beijing 100034, China
  • Received:2022-05-13 Revised:2022-08-08 Online:2022-12-12 Published:2022-12-12
  • Contact: 100034 北京，1北京大学第一医院肾脏内科，北京大学肾脏疾病研究所，卫生部肾脏疾病重点实验室，教育部慢性肾脏疾病预防与治疗重点实验室，中国医学科学院免疫介导肾病诊治创新单元 E-mail:jie.dong@bjmu.edu.cn

PDF

133

摘要： 慢性肾脏病(chronic kidney disease，CKD)全球患病率高，社会负担重，其常见并发症高钾血症是一种可危及生命的电解质紊乱，与患者全因和心血管死亡率升高显著相关。同时，CKD合并心血管疾病需要使用肾素-血管紧张素-醛固酮系统拮抗剂(renin-angiotensin-aldosterone system inhibitor，RAASi)，可加重高钾血症风险，并转而限制RAASi在该人群中的应用。因此，使用合理的钾结合剂对改善CKD患者整体预后和减轻患者经济负担具有重大意义。本综述旨在对Patiromer和环硅酸锆钠(sodium zirconium cyclosilicate，SZC)在CKD患者中应用的研究进行归纳和总结，以期对后续研究开展提供参考。

关键词: 慢性肾脏病, 高钾血症, Patiromer, 环硅酸锆钠

Abstract: Chronic kidney disease (CKD) is a worldwide disease with higher prevalence, and makes a tremendous burden to the societies. Hyperkalemia is a common and  life-threatening electrolyte imbalance complication, and is closely related to the higher all-cause and cardiovascular mortality of this disease. Meanwhile, the use of renin-angiotensin-aldosterone system inhibitor (RAASi) in CKD patients with cardiovascular disease aggravates the risk of hyperkalemia, which may limit the use of RAASi in this particular population. Therefore, appropriate use of potassium-binding agents is of great significance to improve the overall prognosis and to relieve their economic burden. This review aims to summarize the application of patiromer and sodium zirconium cyclosilicate (SZC) in CKD patients in order to provide references for further studies.

Key words: Chronic kidney disease, Hyperkalemia, Patiromer, Sodium zirconium cyclosilicate

中图分类号: